The Food and Drug Administration (FDA) announces it has approved Aemcolo (rifamycin), an antibacterial drug indicated for the treatment of adult patients with travelers’ diarrhea caused by noninvasive strains of Escherichia coli (E. coli), not complicated by fever or blood in the stool.
Hepatitis C drugs cure more than 90 percent of patients, but can cost more than $50,000 per patient.
The following is a statement from FDA commissioner Scott Gottlieb, MD, on new steps to strengthen and modernize agency’s oversight and reporting of inspections for sterile injectable drugs:
The Food and Drug Administration (FDA) announces it has approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48 hours.
The Food and Drug Administration (FDA) today approved a new drug, Arikayce (amikacin liposome inhalation suspension), for the treatment of lung disease caused by a group of bacteria, Mycobacterium avium complex (MAC) in a limited populati
The lack of new antibiotics is among the most critical challenges facing medicine. Researchers have been on the hunt for new drugs to combat "superbugs" that cannot be penetrated by current antibiotics.
The Infectious Diseases Society of America (IDSA) and the The HIV Medicine Association (HIVMA) have issued the following statement:
Enrollment has begun in a Phase 1 clinical trial to test the safety of a new investigational drug designed to treat malaria, as well as its effect on the human body.
A single dose of a new influenza drug can significantly shorten the duration of the illness in teens and adults, according to a study published in the New England Journal of Medicine.
The National Academies of Sciences, Engineering, and Medicine (NASEM) today released proceedings of a March 12 workshop exploring the rise in infectious diseases accompanying opioid abuse, and possible strategies for reducing both epidemi